# Peanut Epicutaneous Phase II Immunotherapy Clinical Trial

> **NCT01904604** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 75 (actual)

## Conditions studied

- Peanut Hypersensitivity
- Food Hypersensitivity
- Hypersensitivity
- Hypersensitivity, Immediate

## Interventions

- **BIOLOGICAL:** Placebo Viaskin® Patch
- **BIOLOGICAL:** Low-dose DBV712 Viaskin® Patch
- **BIOLOGICAL:** High-dose DBV712 Viaskin® Patch

## Key facts

- **NCT ID:** NCT01904604
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2015-08
- **Final completion:** 2018-08-21
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2019-07-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01904604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01904604, "Peanut Epicutaneous Phase II Immunotherapy Clinical Trial". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01904604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*